



August 19, 2024

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai – 400 001  
**Scrip code: 532531**

**The National Stock Exchange of India Limited**  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E) Mumbai - 400 051  
**Scrip code: STAR**

Dear Madam/ Sir

**Reg: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Sub: EIR from USFDA on continued GMP status for the facility in Alathur, Chennai**

We would like to update you that Strides Alathur Private Limited, a wholly owned subsidiary of Strides Pharma Science Limited (Strides) has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for its formulations facility at Alathur, Chennai thereby successfully concluding the Good Manufacturing Practices (GMP) inspection conducted between April 1-5, 2024. USFDA has determined that the inspection classification of this facility is “Voluntary Action Indicated” (VAI).

Strides Alathur facility caters to the U.S. and Other Regulated Markets. The facility manufactures tablets & capsules and supports several current and future products for the US markets.

Strides remains committed to the highest standards of compliance and will continue to focus on manufacturing high-quality pharmaceutical products for the Global markets.

We request that you take the above on record.

Thanks & Regards,  
**For Strides Pharma Science Limited**

**Manjula Ramamurthy**  
**Company Secretary**  
**ICSI Membership No. A30515**

**Strides Pharma Science Limited**

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com